- Home
- INAB vs GENK Comparison
INAB vs GENK Comparison
Compare INAB & GENK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INAB | GENK |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | 2700 |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 12.8M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | INAB | GENK |
|---|---|---|
| Price | $1.10 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $4.50 |
| AVG Volume (30 Days) | 59.6K | ★ 85.6K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 1.88% |
| EPS Growth | N/A | ★ 62.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $208,380,000.00 |
| Revenue This Year | N/A | $4.79 |
| Revenue Next Year | N/A | $7.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.12 |
| 52 Week Low | $0.88 | $1.43 |
| 52 Week High | $2.73 | $3.25 |
Technical Indicators
Market Signals| Indicator | INAB | GENK |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 42.70 |
| Support Level | $0.92 | $1.73 |
| Resistance Level | $1.50 | $2.15 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 39.71 | 23.53 |
Price Performance
Historical ComparisonAbout INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.